Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology - Summary - MDSpire

Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology

The American Society of Hematology is recognizing 11 distinguished hematologists with its most prestigious awards and named lectures, honoring transformative contributions that have advanced research, patient care, and education in blood disorders. Two of this year’s honorees are from Dana-Farber Cancer Institute: Benjamin L. Ebert, MD, PhD, and Scott A. Armstrong, MD, PhD.

  • By

  • June 23, 2026

  • 4 min

Share

Objective:

To recognize distinguished hematologists for their transformative contributions to research, patient care, and education in blood disorders.

Approach:
  • Recognition of Awards: The American Society of Hematology honors 11 hematologists with prestigious awards for their contributions to the field.
  • Honorees from Dana-Farber: Benjamin L. Ebert, MD, PhD, and Scott A. Armstrong, MD, PhD, from Dana-Farber Cancer Institute are among the honorees.
Key Findings:
  • Benjamin L. Ebert received the Janet Rowley Basic Science Medal for his contributions to blood cancer research, including discoveries related to multiple myeloma and myelodysplastic syndrome.
  • Scott A. Armstrong was awarded the E. Donnall Thomas Lecture and Prize for his research on leukemia, particularly MLL-rearranged leukemias, which led to the development of new therapeutic strategies, including FDA-approved menin inhibitors.
Interpretation:

The awards highlight significant advancements in hematology research and treatment, reflecting the honorees' impact on patient care.

Conclusion:

The awards will be presented at the 2026 ASH Annual Meeting in New Orleans, LA.

Sources:

Original Source(s)

Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology

  • by

  • June 23, 2026

Related Content

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

  • 1 min
Roswell Park Launches Exclusive Phase 1 Clinical Trial of ‘Armored’ CAR T-Cell Therapy for Ovarian Cancer

Roswell Park Comprehensive Cancer Center is currently recruiting for a phase 1 clinical trial of the new therapy (NCT07489287), called GB-5267, which was co-developed by Roswell Park and the therapeutics company Generate:Biomedicines.

  • June 24, 2026

  • 3 min
Inside the Rise of circRNA

Circio CEO Erik Wiklund reflects on the discovery of human circular RNA and its evolution into a fast-moving therapeutic modality

  • July 9, 2026

  • 12 min